176 related articles for article (PubMed ID: 37490060)
1. Low-intensity laser diode plus extracorporeal shock wave therapy: a new treatment strategy in the management of Peyronie's disease.
Dell'Atti L; Ronchi P
World J Urol; 2023 Sep; 41(9):2563-2568. PubMed ID: 37490060
[TBL] [Abstract][Full Text] [Related]
2. Shockwave Therapy in the Treatment of Peyronie's Disease.
Krieger JR; Rizk PJ; Kohn TP; Pastuszak A
Sex Med Rev; 2019 Jul; 7(3):499-507. PubMed ID: 30926460
[TBL] [Abstract][Full Text] [Related]
3. [Low-intensity extracorporeal shockwave therapy for Peyronie's disease: A preliminary study of 32 cases].
Li PC; Chen X; Zhu XB; Shi T; Song F; Huang HW; Zhang XS
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):340-344. PubMed ID: 30168955
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal Shockwave Therapy in Peyronie's Disease: Systematic Review and Meta-Analysis.
Bakr AM; El-Sakka AI
J Sex Med; 2021 Oct; 18(10):1705-1714. PubMed ID: 34511369
[TBL] [Abstract][Full Text] [Related]
5. Serum Testosterone Concentration Influences the Response to Extracorporeal Shock Wave Treatment in Men With Peyronie's Disease.
Dell'Atti L; Slyusar V; Ronchi P
Urology; 2024 Jan; 183():111-116. PubMed ID: 37832829
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity.
Strebel RT; Suter S; Sautter T; Hauri D
Int J Impot Res; 2004 Oct; 16(5):448-51. PubMed ID: 14973523
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal shockwave therapy for Peyronie's disease: an alternative treatment?
Poulakis V; Skriapas K; de Vries R; Dillenburg W; Ferakis N; Witzsch U; Melekos M; Becht E
Asian J Androl; 2006 May; 8(3):361-6. PubMed ID: 16625288
[TBL] [Abstract][Full Text] [Related]
8. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease.
Palmieri A; Imbimbo C; Longo N; Fusco F; Verze P; Mangiapia F; Creta M; Mirone V
Eur Urol; 2009 Aug; 56(2):363-9. PubMed ID: 19473751
[TBL] [Abstract][Full Text] [Related]
9. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients.
Porst H
Sex Med Rev; 2021 Jan; 9(1):93-122. PubMed ID: 32499189
[TBL] [Abstract][Full Text] [Related]
10. Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study.
Hatzichristodoulou G; Meisner C; Gschwend JE; Stenzl A; Lahme S
J Sex Med; 2013 Nov; 10(11):2815-21. PubMed ID: 23898925
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of extracorporeal shock wave therapy for acute Peyronie's disease: a 10-year retrospective analysis.
Spirito L; Manfredi C; La Rocca R; Napolitano L; Preto M; Di Girolamo A; Arcaniolo D; De Sio M; Creta M; Longo N
Int J Impot Res; 2024 Apr; 36(2):135-139. PubMed ID: 36788352
[TBL] [Abstract][Full Text] [Related]
12. Long-term experiences with high-energy shock wave therapy in the management chronic phase Peyronie's disease using two different electromagnetic lithotripters.
Rassweiler JJ; Scheitlin W; Goezen AS; Radecke F
World J Urol; 2024 Mar; 42(1):124. PubMed ID: 38453751
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie's disease, erectile dysfunction and chronic pelvic pain.
Fojecki GL; Tiessen S; Osther PJ
World J Urol; 2017 Jan; 35(1):1-9. PubMed ID: 27108421
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of extracorporeal shockwave therapy for Peyronie's disease.
Srirangam SJ; Manikandan R; Hussain J; Collins GN; O'Reilly PH
J Endourol; 2006 Nov; 20(11):880-4. PubMed ID: 17144855
[TBL] [Abstract][Full Text] [Related]
15. A new alternative approach to management of acute phase Peyronie's disease: low intensity extracorporeal shockwave therapy and platelet-rich plasma.
Karakose A; Yitgin Y
Minerva Urol Nephrol; 2024 Jun; 76(3):367-372. PubMed ID: 38093617
[TBL] [Abstract][Full Text] [Related]
16. Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.
Abdessater M; Akakpo W; Kanbar A; Parra J; Seisen T; Chartier-Kastler E; Drouin SJ; Roupret M
Asian J Androl; 2022; 24(1):45-49. PubMed ID: 34045390
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.
Palmieri A; Imbimbo C; Creta M; Verze P; Fusco F; Mirone V
Int J Androl; 2012 Apr; 35(2):190-5. PubMed ID: 22085227
[TBL] [Abstract][Full Text] [Related]
18. [Extracorporeal shock wave therapy for Peyronie's disease].
Ochoa A; Guillot-Tantay C; Faix A; Misrai V; Rouprêt M
Prog Urol; 2020 Sep; 30(10):488-499. PubMed ID: 32370921
[TBL] [Abstract][Full Text] [Related]
19. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach.
Hauck EW; Hauptmann A; Bschleipfer T; Schmelz HU; Altinkilic BM; Weidner W
J Urol; 2004 Jan; 171(1):296-9. PubMed ID: 14665898
[TBL] [Abstract][Full Text] [Related]
20. Multimodal treatments based on Tadalafil during acute phase of Peyronie's disease: experience at two referral academic centers.
Dell'Atti L; Slyusar V; Cambise C
Ir J Med Sci; 2024 Jun; ():. PubMed ID: 38861101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
